A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine

Eli Lilly and Company9 sites in 1 country38 target enrollmentNovember 16, 2020

ConditionsMigraine

InterventionsLY3451838 Placebo

DrugsLY3451838 Placebo

Overview

Phase: Phase 2
Intervention: LY3451838
Conditions: Migraine
Sponsor: Eli Lilly and Company
Enrollment: 38
Locations: 9
Primary Endpoint: Change From Baseline in the Number of Monthly Migraine Headache Days During 1-Month
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.

Registry

clinicaltrials.gov

Start Date

November 16, 2020

End Date

November 9, 2022

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Eli Lilly and Company

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Must have a diagnosis of migraine with a history of migraine headaches of at least 1 year prior, and migraine onset prior to age
•Have completed at least 80% of required daily diary entries during the start of the study.
•Have documentation of previous failure of 2 to 4 standard-of-care migraine preventive medication categories in the past 10 years.
•Women of child-bearing potential must test negative for pregnancy as indicated by a negative serum pregnancy test and negative urine pregnancy test.
•Women of child-bearing potential who are abstinent or in a same sex relationship must agree to either remain abstinent or to avoid sexual relationships with males.
•Women of child-bearing potential who are not abstinent, must agree to use one highly effective method of contraception, or a combination of two effective methods of contraception during the study, as well as 5 months following.
•Women not of childbearing potential may participate and include those who are: A. Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal ligation) or congenital anomaly; or B. Post-menopausal - defined as either:
•i. a woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, and a follicle-stimulating hormone greater than (\>) 40 multi-international units per milliliter (mIU/mL); or
•ii. a woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea; or
•iii. a woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy

Exclusion Criteria

•Are currently enrolled in any other clinical study or any other type of medical research judged not to be compatible with this study.
•Have participated, within the last 30 days or 5-half-lives (whichever is longer), in a clinical study involving any investigational product. If the half-life of the investigational product is unknown, 6 months should have passed prior.
•Known hypersensitivity or intolerance to monoclonal antibodies or other therapeutic proteins, or to common antihistamines, epinephrine, methyl prednisone or other systemic corticosteroids.
•Are currently receiving medication or other treatment for prevention of migraine headaches. Participants must have discontinued such medications or treatments at least 2 weeks prior. Botulinum toxin A or B that has been administered in the head or neck area use must be discontinued at least 3 months prior. Nerve blocks or device use (such as transcranial magnetic stimulation or electrical nerve stimulation) in the head or neck area for migraine treatment must be discontinued at least 30 days prior. Anti-calcitonin gene-related peptide (CGRP) antibodies must be discontinued at least 5 half-lives prior.
•Have previously failed more than 4 migraine preventive medication categories in the past 10 years due to inadequate efficacy (that is, maximum tolerated dose for at least 2 months) and/or safety / tolerability reasons.
•History of cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, retinal migraine, typical aura without headache, complications of migraine and migraine with brainstem aura (basilar-type migraine).
•In the 3 months prior, have other types of headache besides migraine, tension type headache, or medication overuse headache (MOH). (In other words, participants can have migraine, tension type headache, or MOH in the 3 months prior, but they cannot have other types of headache in that time).
•History of head or neck injury within last 6 months.
•History of traumatic cervical or head injury associated with significant change in the quality or frequency of headaches.
•Have reading of electrocardiogram (ECG) showing abnormalities considered incompatible with the study.

Arms & Interventions

1500 milligrams (mg) LY3451838

Participants received a single intravenous (IV) dose of 1500 mg LY3451838.

Intervention: LY3451838

Placebo

Participants received a single IV dose of placebo.

Intervention: Placebo

Outcomes

Primary Outcomes

Change From Baseline in the Number of Monthly Migraine Headache Days During 1-Month

Time Frame: Baseline, Month 1

Migraine Headache Day is a calendar day on which a migraine or probable migraine headache occurs. Per International Headache Society \[IHS\] International Classification of Headache Disorders version 3 \[ICHD-3\], migraine is defined as a headache, with or without aura, of \>=30 minutes duration with both of the following required features (A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity (B) During headache at least 1 of the following: Nausea and/or vomiting; Photophobia and phonophobia. Least square mean was assessed using Bayesian Mixed Model Analysis with baseline number of monthly migraine headache days as a covariate.

Secondary Outcomes

Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs)(Baseline up to 5 Months)
Change From Baseline in the Number of Monthly Headache Days During 3-Month(Baseline, Month 3)
Percentage of Participants With ≥50% Reduction From Baseline in Monthly Migraine Headache Days(Month 1)
Number of Participants With at Least One Serious Adverse Events (SAEs)(Baseline up to 5 Months)
Pharmacokinetics (PK): Area Under the Serum Concentration-time Curve From Time 0 to the Last Measurable Serum Concentration (AUC 0-t) of LY3451838(Pre-infusion, end of infusion, 3hours(h), 365h, 730h, 1095h, 1460h, 1825h, 2190h, 2920h, 3650h post-infusion)
PK: Maximum Observed Serum Concentration (Cmax) of LY3451838(Pre-infusion, end of infusion, 3hours(h), 365h, 730h, 1095h, 1460h, 1825h, 2190h, 2920h, 3650h post-infusion)